VIVUS Reports Second Quarter 2009 Financi...(-302) will determine the impact of Qnexa...),Health

Date:8/11/2009

-302) will determine the impact of Qnexa on patients that are considered morbidly obese (BMI>35). The CONQUER study (OB-303) enrolled patients that are considered overweight (BMI>27) with at least two co-morbidities including high blood pressure, high cholesterol and type 2 diabetics. Top-line results for both of these studies are expected in the third quarter of 2009.

"The highlight of the second quarter was the two podium presentations of Qnexa at this year's American Diabetes Association Scientific Session. The medical and scientific communities have long recognized the link between obesity and type 2 diabetes. Now they are beginning to recognize the importance of weight loss in the treatment of type 2 diabetes. The top-line results from the year-long studies of Qnexa for the treatment of obesity are expected in the third quarter of 2009. Progress on the preparation of the NDA for Qnexa in obesity also remains on schedule for an expected filing by the end of 2009," stated Leland Wilson, president and chief executive officer of VIVUS. "Pivotal studies for avanafil for the treatment of erectile dysfunction are also in process, with results expected in the fourth quarter of 2009."

About VIVUS

VIVUS is a biopharmaceutical company developing innovative, next-generation therapies to address obesity, diabetes and sexual health. The company's lead product in clinical development, Qnexa(TM), is expected to complete phase 3 clinical trials for the treatment of obesity in 2009. Qnexa is also in phase 2 clinical development for the treatment of type 2 diabetes. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a PDE5 inhibitor, and in phase 3 development of Luramist(TM) for the treatment of hypoactive sexual desire disorder (HSDD). For more information about the company, please visit www.vivus.com'/>"/>

SOURCE VIVUS, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7
Related medicine news :

1. VIVUS Qnexa Shows Significantly Improved Blood Sugar Control Through Weight Loss In Patients With Type 2 Diabetes
2. Mesa Labs Reports Higher First Quarter Earnings
3. Physician Owned and Operated Hospitals Get Top Rankings From Consumer Reports, but They Remain on the Healthcare Reform Chopping Block
4. Cardium Reports on Second Quarter 2009 Financial Results and Recent Developments
5. Winner Medical Reports Third Quarter Fiscal 2009 Results
6. Vion Pharmaceuticals Reports 2009 Second Quarter And Six-Month Results
7. DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financial Results
8. Cornerstone Therapeutics Reports Second Quarter and First Half 2009 Financial Results
9. Cardiac Science Reports Q2 Revenue; Resumes AED Shipments
10. PAREXEL International Reports Fourth Quarter and Fiscal Year 2009 Results
11. Milestone Scientific Reports 44% Increase in Revenues in First Six Months of 2009 Compared to Prior Year